420 related articles for article (PubMed ID: 11709315)
1. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants.
Gubareva LV; Webster RG; Hayden FG
Antimicrob Agents Chemother; 2001 Dec; 45(12):3403-8. PubMed ID: 11709315
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir.
Bantia S; Parker CD; Ananth SL; Horn LL; Andries K; Chand P; Kotian PL; Dehghani A; El-Kattan Y; Lin T; Hutchison TL; Montgomery JA; Kellog DL; Babu YS
Antimicrob Agents Chemother; 2001 Apr; 45(4):1162-7. PubMed ID: 11257030
[TBL] [Abstract][Full Text] [Related]
3. Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors.
Boivin G; Goyette N
Antiviral Res; 2002 Jun; 54(3):143-7. PubMed ID: 12062387
[TBL] [Abstract][Full Text] [Related]
4. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses.
Govorkova EA; Leneva IA; Goloubeva OG; Bush K; Webster RG
Antimicrob Agents Chemother; 2001 Oct; 45(10):2723-32. PubMed ID: 11557461
[TBL] [Abstract][Full Text] [Related]
5. Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir.
Hurt AC; Barr IG; Hartel G; Hampson AW
Antiviral Res; 2004 Apr; 62(1):37-45. PubMed ID: 15026200
[TBL] [Abstract][Full Text] [Related]
6. Identification of a human influenza type B strain with reduced sensitivity to neuraminidase inhibitor drugs.
Hurt AC; McKimm-Breschkin JL; McDonald M; Barr IG; Komadina N; Hampson AW
Virus Res; 2004 Jul; 103(1-2):205-11. PubMed ID: 15163511
[TBL] [Abstract][Full Text] [Related]
7. Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay.
Gubareva LV; Webster RG; Hayden FG
Antiviral Res; 2002 Jan; 53(1):47-61. PubMed ID: 11684315
[TBL] [Abstract][Full Text] [Related]
8. In vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675.
Molla A; Kati W; Carrick R; Steffy K; Shi Y; Montgomery D; Gusick N; Stoll VS; Stewart KD; Ng TI; Maring C; Kempf DJ; Kohlbrenner W
J Virol; 2002 Jun; 76(11):5380-6. PubMed ID: 11991966
[TBL] [Abstract][Full Text] [Related]
9. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir.
McKimm-Breschkin J; Trivedi T; Hampson A; Hay A; Klimov A; Tashiro M; Hayden F; Zambon M
Antimicrob Agents Chemother; 2003 Jul; 47(7):2264-72. PubMed ID: 12821478
[TBL] [Abstract][Full Text] [Related]
10. Mechanism by which mutations at his274 alter sensitivity of influenza a virus n1 neuraminidase to oseltamivir carboxylate and zanamivir.
Wang MZ; Tai CY; Mendel DB
Antimicrob Agents Chemother; 2002 Dec; 46(12):3809-16. PubMed ID: 12435681
[TBL] [Abstract][Full Text] [Related]
11. Surveillance for neuraminidase inhibitor resistance in human influenza viruses from Australia.
Hurt AC; Barr IG; Durrant CJ; Shaw RP; Sjogren HM; Hampson AW
Commun Dis Intell Q Rep; 2003; 27(4):542-7. PubMed ID: 15508516
[TBL] [Abstract][Full Text] [Related]
12. Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice.
Ferraris O; Kessler N; Lina B
Antiviral Res; 2005 Oct; 68(1):43-8. PubMed ID: 16125799
[TBL] [Abstract][Full Text] [Related]
13. A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A/H1N1 virus.
Abed Y; Goyette N; Boivin G
Antivir Ther; 2004 Aug; 9(4):577-81. PubMed ID: 15456089
[TBL] [Abstract][Full Text] [Related]
14. Phenotypic drug susceptibility assay for influenza virus neuraminidase inhibitors.
McSharry JJ; McDonough AC; Olson BA; Drusano GL
Clin Diagn Lab Immunol; 2004 Jan; 11(1):21-8. PubMed ID: 14715540
[TBL] [Abstract][Full Text] [Related]
15. Surveillance of influenza isolates for susceptibility to neuraminidase inhibitors during the 2000-2002 influenza seasons.
Mungall BA; Xu X; Klimov A
Virus Res; 2004 Jul; 103(1-2):195-7. PubMed ID: 15163509
[TBL] [Abstract][Full Text] [Related]
16. In vitro generation and characterisation of an influenza B variant with reduced sensitivity to neuraminidase inhibitors.
Cheam AL; Barr IG; Hampson AW; Mosse J; Hurt AC
Antiviral Res; 2004 Sep; 63(3):177-81. PubMed ID: 15451185
[TBL] [Abstract][Full Text] [Related]
17. Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities.
Smee DF; Huffman JH; Morrison AC; Barnard DL; Sidwell RW
Antimicrob Agents Chemother; 2001 Mar; 45(3):743-8. PubMed ID: 11181354
[TBL] [Abstract][Full Text] [Related]
18. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility.
Yen HL; Herlocher LM; Hoffmann E; Matrosovich MN; Monto AS; Webster RG; Govorkova EA
Antimicrob Agents Chemother; 2005 Oct; 49(10):4075-84. PubMed ID: 16189083
[TBL] [Abstract][Full Text] [Related]
19. Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro.
Zürcher T; Yates PJ; Daly J; Sahasrabudhe A; Walters M; Dash L; Tisdale M; McKimm-Breschkin JL
J Antimicrob Chemother; 2006 Oct; 58(4):723-32. PubMed ID: 16891631
[TBL] [Abstract][Full Text] [Related]
20. In vivo influenza virus-inhibitory effects of the cyclopentane neuraminidase inhibitor RJW-270201.
Sidwell RW; Smee DF; Huffman JH; Barnard DL; Bailey KW; Morrey JD; Babu YS
Antimicrob Agents Chemother; 2001 Mar; 45(3):749-57. PubMed ID: 11181355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]